Beximco PharmaceuticalsBXMPY 91 Shareholder Yield % is 2.09% as of Mar. 2026, which is 9% below its 10-year median of 2.29. GuruFocus rates BXMPY with a GF Score™ of 91/100. The stock has 4 warning signs investors should review. Among 970 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 65.15% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Beximco Pharmaceuticals's Shareholder Yield % was 2.09%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Beximco Pharmaceuticals Shareholder Yield % Related Terms
Beximco Pharmaceuticals Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Beximco Pharmaceuticals's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BXMPY vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Beximco Pharmaceuticals (BXMPY) has a Shareholder Yield % of 2.09% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Beximco Pharmaceuticals and its competitors. This is near median its historical median of 2.29. According to the industry distribution chart, Beximco Pharmaceuticals ranks #338 out of 970 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is Beximco Pharmaceuticals' Shareholder Yield % too high?
Beximco Pharmaceuticals' current Shareholder Yield % of 2.09% is near median its 10-year median of 2.29. The Drug Manufacturers industry median Shareholder Yield % is 0.34. Beximco Pharmaceuticals' value of 2.09% is 523.9% above this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #338 out of 970 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #338 out of 970 companies for Shareholder Yield %. This puts Beximco Pharmaceuticals in the upper half of its industry. The industry median Shareholder Yield % is 0.34. Beximco Pharmaceuticals' value of 2.09% is 523.9% above this benchmark. While the company's 10-year median is 2.29 vs. the industry median of 0.34, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.34, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current Shareholder Yield % of 2.09% is 523.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Shareholder Yield % is 2.09%, which is near median its own 10-year median of 2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Shareholder Yield % of 2.09%. The current Shareholder Yield % is 2.09%, which is near median its 10-year median of 2.29 and 523.9% above the Drug Manufacturers industry median of 0.34. Beximco Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Shareholder Yield % is 2.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 